Nefopam

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Nefopam is a non-opioid analgesic used for moderate to severe pain, especially post-surgical pain.

Generic Name
Nefopam
DrugBank Accession Number
DB12293
Background

Nefopam is under investigation for the prevention of Cholecystitis and Post Anaesthetic Shivering. Nefopam has been investigated for the prevention of Kidney Transplantation.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Weight
Average: 253.345
Monoisotopic: 253.146664236
Chemical Formula
C17H19NO
Synonyms
  • Nefopam

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Symptomatic treatment ofPain•••••••••••••••••••••• ••••••••• ••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
MorphineThe therapeutic efficacy of Morphine can be increased when used in combination with Nefopam.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Nefopam hydrochloride685J48E13W23327-57-3CNNVSINJDJNHQK-UHFFFAOYSA-N

Categories

ATC Codes
N02BG06 — Nefopam
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
Aralkylamines
Alternative Parents
Benzene and substituted derivatives / Trialkylamines / Oxacyclic compounds / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Dialkyl ether / Ether / Hydrocarbon derivative / Monocyclic benzene moiety / Organic oxygen compound / Organoheterocyclic compound
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
4UP8060B7J
CAS number
13669-70-0
InChI Key
RGPDEAGGEXEMMM-UHFFFAOYSA-N
InChI
InChI=1S/C17H19NO/c1-18-11-12-19-17(14-7-3-2-4-8-14)16-10-6-5-9-15(16)13-18/h2-10,17H,11-13H2,1H3
IUPAC Name
5-methyl-1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine
SMILES
CN1CCOC(C2=CC=CC=C2)C2=CC=CC=C2C1

References

General References
  1. INVIMA Product Authorization: Katamox (nefopam hydrochloride) injectable solution [Link]
PubChem Compound
4450
PubChem Substance
347828561
ChemSpider
4295
BindingDB
50237616
RxNav
7285
ChEBI
88318
ChEMBL
CHEMBL465026
Wikipedia
Nefopam

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentPostoperative pain1
4RecruitingPreventionAdverse Effects in the Therapeutic Use of Anaesthetics / Shivering1
4TerminatedTreatmentPostoperative Analgesia1
4Unknown StatusPreventionGallbladder Inflammation1
4Unknown StatusTreatmentRenal Colic1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionIntramuscular; Intravenous20 mg/1ml
SolutionIntramuscular; Intravenous20 mg
SolutionIntramuscular; Intravenous
SolutionIntramuscular20 mg
Tablet
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0803 mg/mLALOGPS
logP3.16ALOGPS
logP3.4Chemaxon
logS-3.5ALOGPS
pKa (Strongest Basic)7.72Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area12.47 Å2Chemaxon
Rotatable Bond Count1Chemaxon
Refractivity78.48 m3·mol-1Chemaxon
Polarizability29.09 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0090000000-d615d88ca7a2d989ef60
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0090000000-a3da58efff446fe81400
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-1290000000-55a4914f77fa1a7805c7
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-02t9-1960000000-beb84283a1cd8aa432a7
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-9500000000-6872fd1610e7227c5735
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-3900000000-e115eeb6f1fab677a0c2
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-153.82016
predicted
DeepCCS 1.0 (2019)
[M+H]+156.17818
predicted
DeepCCS 1.0 (2019)
[M+Na]+162.27132
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 21:51 / Updated at May 27, 2021 03:04